钙卫蛋白在肿瘤坏死因子抑制剂治疗幼年特发性关节炎临床应答中的预测作用

发布时间：2018-05-07 04:12

本文选题：幼年特发性关节炎 + 钙卫蛋白　；参考：《中国医科大学学报》2017年09期

【摘要】：目的评估血清钙卫蛋白(MRP8/14)水平在肿瘤坏死因子(TNF)抑制剂治疗中国人群幼年特发性关节炎(JIA)患者临床应答中的预测作用。方法纳入72例接受依那西普治疗24周的JIA患者和30例健康志愿者(HCs),采用免疫酶吸附法检测JIA患者基线期和HCs血清MRP8/14水平。临床应答定义为实现ACR儿科临床应答标准ACRpedi 50。结果 JIA患者中血清MRP8/14水平显著高于HCs(P0.001)。基线期应答组患者血清MRP8/14水平显著高于不应答组(P0.001)。受试者工作特征曲线显示,MRP8/14水平预测临床应答曲线下面积为0.823(95%CI:0.706~0.939)。进一步行单因素、多因素logistic回归分析发现,血清MRP8/14高水平是临床应答的独立预测因素(P=0.003)。结论血清MRP8/14水平可作为可靠的、新颖的预测TNF抑制剂治疗JIA患者临床应答的生物标志物。
[Abstract]:Objective to evaluate the predictive effect of serum calcitonin 8 / 14 (MRP 8 / 14) level on the clinical response of patients with juvenile idiopathic arthritis (JIA) treated with TNFI inhibitor. Methods 72 patients with JIA and 30 healthy volunteers who were treated with enazepril for 24 weeks were enrolled in this study. The serum MRP8/14 levels of JIA patients in baseline and HCs were measured by immunosorbent assay. Clinical response is defined as the realization of ACR pediatric clinical response standard ACRpedi 50. Results the serum MRP8/14 level in patients with JIA was significantly higher than that in patients with JIA (P 0.001). The serum MRP8/14 level in the baseline response group was significantly higher than that in the non-response group (P 0. 001). The area under the MRP 8 / 14 predicted clinical response curve was 0.823 ~ 95% CI: 0.706 ~ 0.939%. Further univariate and multivariate logistic regression analysis showed that the high level of serum MRP8/14 was an independent predictor of clinical response. Conclusion Serum MRP8/14 level can be used as a reliable and novel biomarker for predicting the clinical response of JIA patients with TNF inhibitors.
【作者单位】：武汉市妇女儿童医疗保健中心血液肿瘤科;
【分类号】：R725.9

【相似文献】